Regulatory & Market-Entry Questions

Frequently Asked Questions Clear Answers for Complex Regulatory Projects

Find practical answers to common questions about medical device registration, IVDs, pharmaceuticals, clinical research, business compliance, market intelligence and regulated market entry into Bangladesh.

Browse Questions Ask About Your Project

Product Regulation

Business Compliance

Market Access

Ziva DRA Knowledge Desk FAQ

Start with the Question

Regulatory Requirements Depend on the Product and the Project

The FAQ provides general direction. The actual pathway can depend on product classification, intended use, manufacturer status, documentation, market structure and current regulatory requirements.

Devices Registration and market entry

Pharma Dossiers, GMP and medicines

Business Company and compliance

Markets Research and intelligence

Browse by Topic

Jump to the Questions Relevant to Your Project

Medical Devices Registration, classification and local representation.

IVD & Diagnostics Evidence, intended use and registration.

Pharmaceuticals Medicines, dossiers and GMP.

Clinical Research Evidence, protocols and scientific support.

Business Compliance Company, licenses, tax and import structure.

Market Intelligence Research, competitors and market reports.

Global Market Access International expansion and market sequencing.

Working with Ziva DRA Project scope, process and engagement.

Medical Device Registration

Common questions about medical-device regulatory market entry.

Yes. International manufacturers can engage Ziva DRA for product assessment, registration planning, technical-documentation review, local representation, market intelligence and related Bangladesh market-entry support. See Medical Device Registration.

No. The regulatory pathway can vary according to device type, intended use, risk classification, manufacturer information, existing approvals and the applicable regulatory framework. Product assessment should precede a definitive registration plan.

Yes. A documentation-readiness or gap assessment can help identify missing, incomplete or inconsistent information before the submission workstream progresses.

Yes. A broader portfolio can first be assessed collectively and then divided into product-specific regulatory workstreams according to classification, documentation status and strategic priority.

IVD & Diagnostics

Questions concerning diagnostic products and evidence.

Important information can include intended use, analyte or target, specimen type, user, testing environment, technology, performance evidence, manufacturer documentation and existing approvals. See IVD Registration.

Available analytical, clinical or other performance information can be reviewed within the agreed project scope to understand evidence readiness and potential gaps relevant to the regulatory program.

Not automatically. The appropriate product category depends on the equipment, its intended use and the applicable regulatory framework. Equipment should be assessed before assuming an IVD or medical-device pathway.

Pharmaceuticals

Medicine registration, dossier and GMP questions.

Yes. Support can include regulatory assessment, dossier-readiness review, documentation workstreams, GMP-related considerations and connected market-entry planning. See Medicine Registration.

Yes. A dossier-readiness review can help identify documentation gaps, inconsistencies or areas requiring further preparation before submission. See Dossier Preparation.

Yes. Manufacturing and quality readiness can be aligned with the wider registration or pharmaceutical-project strategy when GMP is relevant to the engagement.

Where relevant to the product and regulatory pathway, bioequivalence, clinical research, protocol development and related evidence workstreams can be considered as part of the larger project architecture.

Clinical Research

Clinical-development and evidence-generation questions.

Yes. Protocol development can be structured around the scientific question, study objective, evidence requirements and broader regulatory strategy.

Yes. Early evidence strategy can be valuable because it helps align the study objective with future regulatory and market-access requirements before major study resources are committed.

Scientific and medical writing can be connected with clinical or regulatory projects where documentation and evidence communication form part of the scope.

Business Compliance

Company establishment and operating-compliance questions.

Depending on the project, business-compliance support can include company formation, trade licensing, tax and VAT, import-related requirements, foreign-investment support and related workstreams. See Business Compliance.

Where the business structure is relevant to the regulatory or commercial market-entry model, these workstreams can be coordinated rather than treated as isolated projects.

Yes. Relevant import-registration and associated business-compliance workstreams can be included where applicable to the client's operating model.

BIDA and foreign-investment support fits within the broader Business Compliance architecture and is particularly relevant to foreign investment, company establishment and industrial or healthcare projects.

Market Intelligence

Market research, competitors and commercial decision support.

Yes. Pre-registration market research can help determine whether commercial opportunity justifies regulatory investment. It can examine demand, customer segments, channels, competition and entry barriers.

Yes. Competitor Analysis can examine relevant companies, brands, product portfolios, visible positioning and other agreed competitive factors.

Market Research can focus on specific commercial questions, while a Market Entry Report generally brings multiple dimensions together—such as market structure, competition, regulation, channels, barriers and strategic entry considerations.

Yes. Custom research can be structured around a specific product, industry, customer group, competitor set or strategic decision. See Market Reports.

Global Market Access

International regulatory and expansion questions.

Global Market Access services can support international regulatory strategy, market sequencing and multi-market planning according to the target geographies and product portfolio.

Yes. A multi-market project can compare regulatory and commercial requirements across selected markets to support market prioritization and sequencing.

Yes. Regulatory feasibility is often more useful when considered together with market size, competitive conditions, customer access and commercial priorities.

Working with Ziva DRA

Questions about project scope and engagement.

Start by sharing the product or business category, manufacturer or company information, target market, current documentation and the decision you need to make. Use the Start a Project page.

No. You can describe the project objective and current problem. The workstream can then be structured around the actual regulatory, technical, commercial or business dependencies.

Yes. Complex projects may combine regulatory affairs, clinical research, market intelligence, global market access and business compliance where those workstreams are connected.

Yes. Project structures can support manufacturers, product owners, importers, healthcare businesses, investors, project developers and international market-entry teams depending on the engagement.

Popular Resources

Need More Than a Short Answer?

Move from frequently asked questions to deeper guidance, research and project-specific support.

Regulatory Guides

Practical guidance across device, pharma, diagnostics and compliance topics.

Explore Regulatory Guides →

Insights

Strategic analysis across regulation, market access and healthcare industries.

Explore Insights →

Market Reports

Structured industry and market intelligence for strategic decisions.

Explore Market Reports →

Case Studies

See how complex regulatory and market-entry projects can be structured.

Explore Case Studies →

Downloads

Access checklists, reference documents and practical project resources.

Explore Downloads →

Regulatory Updates

Follow developments affecting regulated products and market access.

Explore Regulatory Updates →

From Question to Workplan

The Right Question Is Often the Beginning of the Regulatory Strategy

A general answer can provide direction, but product-specific decisions require the facts of the actual project.

Clarify the Issue

Define what needs to be understood or resolved.

Assess the Facts

Review the product, company and available information.

Map Dependencies

Connect regulatory, technical and business requirements.

Build the Workplan

Turn uncertainty into defined next steps.

General Information Notice

These FAQs provide general informational guidance only. Regulatory, registration, licensing, tax, import, investment and market-entry requirements can vary according to the product, company, activity, jurisdiction and current regulatory framework. A project-specific assessment should be used before making formal regulatory or business decisions.

Still Have a Regulatory or Market-Entry Question?

Share your product, company, target market, current status and the issue you need to resolve. Ziva DRA can help move the question from general guidance to a structured regulatory, business or market-intelligence workplan.

Ask About Your Project